Background pattern
ZYTIGA 250 mg TABLETS

ZYTIGA 250 mg TABLETS

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use ZYTIGA 250 mg TABLETS

Introduction

Package Leaflet: Information for the User

ZYTIGA 250 mg tablets

abiraterone acetate

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

  1. What ZYTIGA is and what it is used for
  2. What you need to know before you take ZYTIGA
  3. How to take ZYTIGA
  4. Possible side effects
  5. Storage of ZYTIGA
  6. Contents of the pack and other information

1. What ZYTIGA is and what it is used for

ZYTIGA contains the active substance abiraterone acetate. It is used for the treatment of prostate cancer in adult men that has spread to other parts of the body. ZYTIGA stops your body from making testosterone; this can slow down the growth of your prostate cancer.

When ZYTIGA is prescribed in the early stages of the disease and you are still responding to hormone treatment, it is used together with treatment to lower testosterone levels (androgen deprivation treatment).

When you take this medicine, your doctor will also prescribe another medicine called prednisone or prednisolone to reduce the risk of high blood pressure, fluid retention, or low potassium levels in your blood.

2. What you need to know before you take ZYTIGA

Do not take ZYTIGA

  • if you are allergic to abiraterone acetate or any of the other ingredients of this medicine (listed in section 6).
  • if you are a woman, especially if you are pregnant. ZYTIGA is only for use in male patients.
  • if you have severe liver disease.
  • in combination with Ra-223 (used for the treatment of prostate cancer).

Do not take this medicine if any of the above applies to you. If you are not sure, consult your doctor or pharmacist before taking this medicine.

Warnings and precautions

Consult your doctor or pharmacist before starting treatment with this medicine:

  • if you have liver problems
  • if you have been told you have high blood pressure or heart failure or low potassium levels in your blood (low potassium levels in your blood can increase your risk of heart rhythm problems)
  • if you have had other heart or blood vessel problems
  • if you have a fast or irregular heart rhythm
  • if you have difficulty breathing
  • if you have gained weight quickly
  • if you have swelling in your feet, ankles, or legs
  • if you have taken ketoconazole in the past for prostate cancer
  • about the need to take this medicine with prednisone or prednisolone
  • about possible side effects on your bones
  • if you have high blood sugar levels.

Tell your doctor if you have been told you have any heart or blood vessel disorder, including heart rhythm problems (arrhythmia), or if you are being treated with medicines for these disorders.

Tell your doctor if you have yellowing of the skin or eyes, dark urine, or severe nausea or vomiting, as these can be signs of liver problems. Rarely, acute liver failure (which can be life-threatening) may occur.

A decrease in red blood cell count, reduced sexual desire, and cases of muscle weakness and/or muscle pain may occur.

ZYTIGA must not be taken in combination with Ra-223 due to a possible increased risk of bone fractures or death.

If you plan to take Ra-223 after treatment with ZYTIGA and prednisone/prednisolone, you must wait 5 days before starting Ra-223 treatment.

If you are not sure if any of the above applies to you, consult your doctor or pharmacist before taking this medicine.

Blood tests

ZYTIGA may affect your liver even if you have no symptoms. While you are taking this medicine, your doctor will regularly perform blood tests to check for any effect on your liver.

Children and adolescents

This medicine must not be used in children or adolescents. If a child or adolescent accidentally takes ZYTIGA, they should go to the hospital immediately and take this leaflet with them to show to the emergency doctor.

Other medicines and ZYTIGA

Consult your doctor or pharmacist before taking any other medicine.

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This is important because ZYTIGA may increase the effects of certain medicines, including heart medicines, sedatives, some diabetes medicines, herbal medicines (e.g., St. John's Wort), and others. Your doctor may need to change the dose of these medicines. Also, some medicines may increase or decrease the effects of ZYTIGA. This may lead to side effects or ZYTIGA may not work as well as it should.

Androgen deprivation treatment may increase the risk of heart rhythm problems. Tell your doctor if you are being treated with medicines:

  • used to treat heart rhythm problems (e.g., quinidine, procainamide, amiodarone, and sotalol);
  • that increase the risk of heart rhythm problems [e.g., methadone (used for pain relief and as part of drug addiction detoxification), moxifloxacin (an antibiotic), antipsychotics (used for severe mental illnesses)].

Consult your doctor if you are taking any of the medicines listed above.

ZYTIGA with food

  • This medicine must not be taken with food (see section 3, "How to take this medicine").
  • Taking ZYTIGA with food may cause side effects.

Pregnancy and breastfeeding

ZYTIGA is not indicated in women.

  • This medicine may harm the fetus if taken by a pregnant woman.
  • Pregnant women or women who think they may be pregnant should wear gloves if they need to touch or handle ZYTIGA.
  • If you have sex with a woman who can become pregnant, you must use a condom and another effective method of birth control.
  • If you have sex with a pregnant woman, you must use a condom to protect the fetus.

Driving and using machines

It is unlikely that this medicine will affect your ability to drive or use tools or machines.

ZYTIGA contains lactose and sodium

  • ZYTIGA contains lactose. If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.
  • This medicine contains 27.2 mg of sodium (a major component of cooking/table salt) in each dose of four tablets. This is equivalent to 1.36% of the maximum recommended daily intake of sodium for an adult.

3. How to take ZYTIGA

Always take this medicine exactly as your doctor has told you. If you are not sure, consult your doctor or pharmacist.

How much to take

The recommended dose is 1,000 mg (four tablets) once a day.

How to take this medicine

  • Take this medicine by mouth.
  • Do not take ZYTIGA with food.Taking ZYTIGA with food may cause more medicine to be absorbed by the body than necessary, which can cause side effects.
  • Take the ZYTIGA tablets as a single dose once a day on an empty stomach. ZYTIGA should be taken at least 2 hours after eating and no food should be consumed for at least 1 hour after taking ZYTIGA (see section 2, "ZYTIGA with food").
  • Swallow the tablets whole with water.
  • Do not break the tablets.
  • ZYTIGA is given together with a medicine called prednisone or prednisolone. Take prednisone or prednisolone exactly as your doctor has told you.
  • You will need to take prednisone or prednisolone every day while you are taking ZYTIGA.
  • If you have a medical emergency, it may be necessary to adjust the amount of prednisone or prednisolone you take. Your doctor will tell you if you need to change the dose of prednisone or prednisolone. Do not stop taking prednisone or prednisolone unless your doctor tells you to.

Your doctor may also prescribe other medicines while you are taking ZYTIGA and prednisone or prednisolone.

If you take more ZYTIGA than you should

If you take more than you should, consult your doctor or go to the hospital immediately.

If you forget to take ZYTIGA

  • If you forget to take ZYTIGA or prednisone or prednisolone, take your normal dose the next day.
  • If you forget to take ZYTIGA or prednisone or prednisolone for more than one day, consult your doctor immediately.

If you stop taking ZYTIGA

Do not stop taking ZYTIGA or prednisone or prednisolone unless your doctor tells you to.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Stop taking ZYTIGA and contact your doctor immediately if you experience any of the following:

  • Muscle weakness, muscle contractions, or rapid heart rate (palpitations).

These may be signs of low potassium levels in your blood.

Other side effects are:

Very common(may affect more than 1 in 10 people):

Fluid retention in the legs or feet, low potassium levels in the blood, increased liver function tests, high blood pressure, urinary tract infection, diarrhea.

Common(may affect up to 1 in 10 people):

High levels of fats in the blood, chest pain, irregular heart rhythm (atrial fibrillation), heart failure, fast heart rate, severe infections called sepsis, bone fractures, indigestion, blood in the urine, skin rash.

Uncommon(may affect up to 1 in 100 people):

Problems with the adrenal glands (related to problems with salt and water), abnormal heart rhythm (arrhythmia), muscle weakness and/or muscle pain.

Rare(may affect up to 1 in 1,000 people):

Lung inflammation (also called allergic alveolitis).

Acute liver failure (also called acute hepatic failure).

Frequency not known(cannot be estimated from the available data):

Heart attack, changes in the electrocardiogram (ECG) (prolonged QT), and severe allergic reactions with difficulty swallowing or breathing, face, lips, tongue, or throat swelling, or itchy rash.

Bone density loss may occur in men receiving treatment for prostate cancer. ZYTIGA in combination with prednisone or prednisolone may increase this bone density loss.

Reporting of side effects

If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of ZYTIGA

  • Keep this medicine out of the sight and reach of children.
  • Do not use this medicine after the expiry date which is stated on the carton and on the label of the bottle. The expiry date refers to the last day of that month.
  • No special storage conditions are required.
  • Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.

6. Contents of the pack and further information

Composition of ZYTIGA

  • The active substance is abiraterone acetate. Each tablet contains 250 mg of abiraterone acetate.
  • The other ingredients are microcrystalline cellulose, sodium croscarmellose, lactose monohydrate, magnesium stearate, povidone (K29/K32), anhydrous colloidal silica, and sodium lauryl sulfate (see section 2, "ZYTIGA contains lactose and sodium").

Appearance and packaging

  • ZYTIGA tablets are white or almost white, oval (15.9 mm long x 9.5 mm wide), with "AA250" engraved on one side.
  • The tablets are packaged in a plastic bottle with a child-resistant closure. Each bottle contains 120 tablets. Each carton contains one bottle.

Marketing authorisation holder

Janssen-Cilag International NV

Turnhoutseweg 30

B-2340 Beerse

Belgium

Manufacturer

Janssen-Cilag SpA

Via C. Janssen

Borgo San Michele

I-04100 Latina, Italy

You can request more information about this medicine from the local representative of the marketing authorisation holder:

België/Belgique/Belgien

Janssen-Cilag NV

Tel/Tél: +32 14 64 94 11

janssen@jacbe.jnj.com

Lietuva

UAB "JOHNSON & JOHNSON"

Tel: +370 5 278 68 88

lt@its.jnj.com

Text in Bulgarian language including company name 'Johnson & Johnson Bulgaria' and contact details

Luxembourg/Luxemburg

Janssen-Cilag NV

Tel/Tél: +32 14 64 94 11

janssen@jacbe.jnj.com

Ceská republika

Janssen-Cilag s.r.o.

Tel. +420 227 012 227

Magyarország

Janssen-Cilag Kft.

Tel.: +36 1 884 2858

janssenhu@its.jnj.com

Danmark

Janssen-Cilag A/S

Tlf: +45 45 94 82 82

jacdk@its.jnj.com

Malta

AM MANGION LTD.

Tel: +356 2397 6000

Deutschland

Janssen-Cilag GmbH

Tel: +49 2137 955 955

jancil@its.jnj.com

Nederland

Janssen-Cilag B.V.

Tel: +31 76 711 1111

janssen@jacnl.jnj.com

Eesti

UAB "JOHNSON & JOHNSON" Eesti filiaal

Tel: +372 617 7410

ee@its.jnj.com

Norge

Janssen-Cilag AS

Tlf: +47 24 12 65 00

jacno@its.jnj.com

Ελλάδα

Janssen-Cilag Φαρμακευτική Α.Ε.Β.Ε.

Τηλ: +30 210 80 90 000

Österreich

Janssen-Cilag Pharma GmbH

Tel: +43 1 610 300

España

Janssen-Cilag, S.A.

Tel: +34 91 722 81 00

contacto@its.jnj.com

Polska

Janssen-Cilag Polska Sp. z o.o.

Tel.+48 22 237 60 00

France

Janssen-Cilag

Tél: 0 800 25 50 75 / +33 1 55 00 40 03

medisource@its.jnj.com

Portugal

Janssen-Cilag Farmacêutica, Lda.

Tel: +351 214 368 600

Hrvatska

Johnson & Johnson S.E. d.o.o.

Tel: +385 1 6610 700

jjsafety@JNJCR.JNJ.com

România

Johnson & Johnson România SRL

Tel: +40 21 207 1800

Ireland

Janssen Sciences Ireland UC

Tel: +353 1 800 709 122

Slovenija

Johnson & Johnson d.o.o.

Tel: +386 1 401 18 00

Janssen_safety_slo@its.jnj.com

Ísland

Janssen-Cilag AB

c/o Vistor hf.

Sími: +354 535 7000

janssen@vistor.is

Slovenská republika

Johnson & Johnson, s.r.o.

Tel: +421 232 408 400

Italia

Janssen-Cilag SpA

Tel: 800.688.777 / +39 02 2510 1

janssenita@its.jnj.com

Suomi/Finland

Janssen-Cilag Oy

Puh/Tel: +358 207 531 300

jacfi@its.jnj.com

Κύπρος

Βαρνάβας Χατζηπαναγής Λτδ

Τηλ: +357 22 207 700

Sverige

Janssen-Cilag AB

Tfn: +46 8 626 50 00

jacse@its.jnj.com

Latvija

UAB "JOHNSON & JOHNSON" filiale Latvija

Tel: +371 678 93561

lv@its.jnj.com

United Kingdom (Northern Ireland)

Janssen Sciences Ireland UC

Tel: +44 1 494 567 444

Date of last revision of this leaflet:

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu/, and on the Spanish Agency for Medicines and Health Products (AEMPS) web site (http://www.aemps.gob.es/).

Get updates and exclusive offers

Be the first to know about new services, marketplace updates, and subscriber-only promos.

Follow us on social media
FacebookInstagram
Logo
Oladoctor
Find a doctor
Doctors by specialty
Services
Choose language
© 2025 Oladoctor. All rights reserved.
VisaMastercardStripe